Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma
Mogamulizumab (Poteligeo) is indicated for relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - September 11, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 27, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news
PART 2: Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 23, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news
FDA Approves New Drug for Cutaneous T-Cell Lymphomas FDA Approves New Drug for Cutaneous T-Cell Lymphomas
The FDA has granted approval for mogamulizumab-kpkc for adult patients with relapsed or refractory mycosis fungoides or S é zary syndrome.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —PART 1: PTCL-NOS, FTCL, AITL, ALCL
This two-part series highlights the most important aspects of PTCLs and describes current treatment options and investigative opportunities. Part 1 will cover PTCL not otherwise specified, follicular T-cell lymphoma, angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma (ALCL), and breast implant –associated ALCL. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news
Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
STOCKHOLM, June 18, 2018 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Board of Directors have decided to continue the discussions with the US Food and Drug Administration (FDA) to agree on the d... Biopharmaceuticals, Oncology Medivir, remetinostat, cutaneous T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 18, 2018 Category: Pharmaceuticals Source Type: news
Most Breast Implant –Associated Lymphomas Have Indolent Clinical Course
Dave LevitanJun 6, 2018A case series of rare peripheral T-cell lymphoma that is associated with breast implants found that most cases have an indolent clinical course. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news
Sidney Kimmel Cancer Center scientists to present at ASCO Annual Meeting
(Thomas Jefferson University) Scientists from the Sidney Kimmel Cancer Center (SKCC) at Jefferson Health will be presenting research and leading discussions on various topics, including metastatic uveal melanoma, genetic counseling in men, immunotherapy in early stage lung cancer and solid tumors, quality of life among patients receiving treatment for T cell lymphoma and updates on the Cancer Moonshot during the Biden Cancer Initiative Colloquium at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5 in Chicago. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 1, 2018 Category: Cancer & Oncology Source Type: news
Iowa Man's Glyphosate Cancer Case Against Monsanto Sent To Roundup MDL
WASHINGTON, D.C. - The Judicial Panel on Multidistrict Litigation (JPMDL) on May 10 transferred to the multidistrict litigation for Roundup products liability litigation a case in which an Iowa man contends that he developed T-cell lymphoma as a result of exposure to glyphosate and other chemicals in the herbicide Roundup (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - May 15, 2018 Category: Medical Law Source Type: news
New Tool Predicts Deadly Form of Rare Cancer
Genetic sequencing from biopsy can accurately predict which early-stage Cutaneous T Cell Lymphoma (CTCL) patients have aggressive form of this disease (Source: BWH News)
Source: BWH News - May 9, 2018 Category: Hospital Management Source Type: news
Kim Debling shares photos of incurable cancer's disfiguring effects
Kim Debling, 34, from Basingstoke, Hampshire, is virtually unrecognisable after red lumps ravaged her face - caused by her stage four Cutaneous T-Cell lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - May 3, 2018 Category: Consumer Health News Source Type: news
Mother-of-two, 34, with an incurable cancer releases shocking photos of its disfiguring effects
Kim Debling, 34, from Basingstoke, Hampshire, is virtually unrecognisable after red lumps ravaged her face - caused by her stage four Cutaneous T-Cell lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - May 3, 2018 Category: Consumer Health News Source Type: news
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and S ézary Syndrome
A Guide for the Practicing OncologistThird Edition
CLICK HERE TO ACCESS THE WHITE PAPER (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Tags: Sponsored Resources Source Type: news
Rhizen receives USFDA orphan drug designation for cancer drug
The USFDA has granted orphan drug designation for Tenalisib (RP6530)... for the treatment of patients with peripheral T-cell lymphoma (PTCL), Alembic Pharmaceuticals said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 26, 2017 Category: Pharmaceuticals Source Type: news
